— Published Date: 5/14/2025
Value Proposition: Novel antisense oligonucleotide (ASO) directly targeting a microRNA-mediated mechanism responsible for autophagy reduction and neurodegeneration in Huntington’s disease (HD) improving patient outcomes in pre-HD subjects.
Technology Description
R…
— Published Date: 12/21/24
Value proposition: A cost-effective, drug-based therapy targeting the endothelin B receptor (ETBR) to promote peripheral nerve regeneration, offering improved recovery and compatibility with existing treatments.
Technology Description
Researchers at Washington University…
— Published Date: 5/14/2025
Value proposition: Novel ASOs that increase key protein production to limit neurodegeneration caused by ALS and frontotemporal dementia (FTD).
Technology Description
TDP-43 pathology is present in ~97% of ALS, ~50% of FTD, and frequently observed in other neurodegenerat…
— Published Date: 12/20/2024
Value Proposition: Treats brain tumors by combining a hematopoietic growth protein and cancer therapeutics to increase survival rates.
Technology Description
Researchers at Washington University in St. Louis have developed a new way to treat brain cancers by combining…
— Published Date: 12/19/2024
Value proposition: Novel method used to detect tau proteins in the brain using biofluids.
Technology Description
Researchers at Washington University in St. Louis have developed a method to identify and differentiate primary and secondary tauopathies in the brain. Man…
| Name | # Summaries | Author |
|---|---|---|
| 15 | ||
| 13 | ||
| 15 | ||
| 26 | ||
| 14 | ||
| 14 |
Creating...
